Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 1,050,000 shares, a decrease of 16.7% from the August 31st total of 1,260,000 shares. Based on an average daily volume of 325,100 shares, the days-to-cover ratio is currently 3.2 days.
Analyst Ratings Changes
Several analysts recently commented on RZLT shares. Guggenheim started coverage on shares of Rezolute in a research report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Rezolute in a research report on Friday. Craig Hallum assumed coverage on Rezolute in a report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective for the company. Maxim Group upped their target price on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Finally, BTIG Research lifted their price target on shares of Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Rezolute presently has an average rating of “Buy” and a consensus target price of $11.57.
Get Our Latest Stock Report on Rezolute
Institutional Inflows and Outflows
Rezolute Stock Performance
RZLT stock opened at $4.98 on Monday. The company has a market cap of $199.87 million, a price-to-earnings ratio of -4.37 and a beta of 1.18. The business’s 50-day moving average is $4.64 and its two-hundred day moving average is $3.85. Rezolute has a fifty-two week low of $0.72 and a fifty-two week high of $6.10.
Rezolute (NASDAQ:RZLT – Get Free Report) last issued its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.14). Equities analysts predict that Rezolute will post -1.38 earnings per share for the current year.
About Rezolute
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Further Reading
- Five stocks we like better than Rezolute
- 3 Warren Buffett Stocks to Buy Now
- Watch These 3 Former Short-Squeeze Stocks for a Big Rally
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- CarMax’s Impressive Rally: What Investors Should Watch Next
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.